Sign In
Buy ENLV
$6.67
-0.190 (-2.77%)
At Close: Jul 13, 2026
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
01:01pm, Monday, 13'th Jul 2026
Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Monday, 13'th Jul 2026
The heavy selling pressure might have exhausted for Enlivex Ltd. (ENLV) as it is technically in oversold territory now.
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
08:00am, Monday, 13'th Jul 2026
Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administration (
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
08:00am, Tuesday, 07'th Jul 2026
Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split
Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “ Enlivex ” or the “ Company ” ), a quality longevity company powered by a prediction markets treasury, today a
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
08:45am, Monday, 22'nd Jun 2026
Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an up
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
08:00am, Monday, 15'th Jun 2026
Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
08:00am, Tuesday, 02'nd Jun 2026
As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investors Nes-Ziona, Israel, June 02, 2026 (GLOBE
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
08:00am, Monday, 01'st Jun 2026
The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritis Nes-Ziona, Israel, June 01, 2
As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion. Separately, the Rain Foundation recently announced the appointment of five industry leade
Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and K
Enrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency (DKMA) approval received in April 2026 Nes-Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
04:10pm, Friday, 15'th May 2026
Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announc
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
08:30am, Thursday, 30'th Apr 2026
The listing on one of the world's largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex's primary digital treasury asset
New acquisitions from Rain Foundation underlines Enlivex's disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex
